Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-ITCLINICAL PERSPECTIVES

(2015) Erin A. Bohula et al.   CIRCULATION

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study

(2014) A. C. Morton et al.   EUROPEAN HEART JOURNAL

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis

(2013) Brendan M. Everett et al.   AMERICAN HEART JOURNAL

Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD)

(2013) A. B. Goldfine et al.   DIABETES CARE

Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease

(2012) Stefan M. Nidorf et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials

(2011) E. Braunwald   EUROPEAN HEART JOURNAL

Anti-inflammatory effects of the Mediterranean diet: the experience of the PREDIMED study

(2010) Ramon Estruch   PROCEEDINGS OF THE NUTRITION SOCIETY

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET